Royalty Pharma PLC (NASDAQ: RPRX) ticks all the boxes when it comes to stock valuation. The P/E ratio, financials, and growth prospects all go in favour of RPRX. In addition, Royalty Pharma has a 55% market share in drug development and has an economic moat. It's trading way below fair value estimates.
The current P/E ratio of RPRX is 11.11, which is less than the biotech industry average of 15. Regarding book value, RPRX outperforms the industry, having a P/B ratio of 1.64x vs the biotech average of 5.83x.
[
add
]
[
|
|
...
]